In the pursuit of understanding human aging and its implications on health, a remarkable new study has unveiled a ‘proteomic age clock’ that could revolutionize how we tackle age-related diseases.
Type 2 diabetes is a growing concern globally, with projections indicating that by 2045 nearly 11% of the world’s population will be affected. This condition brings with it an increased risk for serious health problems such as hypertension and high cholesterol, which are major culprits behind cardiovascular diseases. Given this situation, researchers are constantly on the lookout for effective interventions.
In this episode, we discuss ketamine as a rapid-acting treatment for depression, potentially helping the brain to heal itself, and investigations of ketamine as a treatment for anxiety and PTSD. We dive deep into the mechanisms of ketamine’s neuroplastic potential in the brain what it means for the future of therapy.
The advent of GLP-1 receptor agonists, such as semaglutide (marketed as Ozempic and Wegovy), has brought promising prospects for weight loss and overall metabolic health improvement (Kim & Kim, 2020). These medications have demonstrated their effectiveness in shedding unwanted pounds and potentially enhancing cardiovascular and metabolic well-being. However, this scientific inquiry delves into a pertinent concern: does the pursuit of weight loss through these pharmacological interventions come at the expense of one’s invaluable muscle mass (Srikanthan & Karlamangla, 2014)? This article will examine the current body of evidence on the impact of GLP-1 receptor agonists on muscle mass and strength, shedding light on whether these benefits indeed come with a price (Ashtary-Larky et al., 2020).
Read more…